HPS/HCPS Clinical Protocols Under Scrutiny Amid Hondius Andes Outbreak
As the MV Hondius Andes remains anchored, medical teams on and off-shore refine Hantavirus Pulmonary Syndrome (HPS) and Hantavirus Cardiopulmonary Syndrome (HCPS) treatment strategies, emphasizing supportive care and advanced life support to manage severe cases.
Supportive Care Remains Cornerstone of Hantavirus Treatment
PRAIA, Cape Verde – With the MV Hondius Andes hantavirus event now in its sixth month, clinical management of Hantavirus Pulmonary Syndrome (HPS) and Hantavirus Cardiopulmonary Syndrome (HCPS) remains a critical focus for international medical teams. Experts from the World Health Organization (WHO) and regional health bodies underscore that supportive care continues to be the primary and most effective intervention for patients experiencing severe HPS/HCPS. There is currently no specific antiviral treatment for hantavirus infections. Instead, medical strategies concentrate on managing symptoms and supporting vital organ function as the body combats the virus. This approach is particularly crucial given the rapid progression of the disease in severe cases.
Respiratory and Hemodynamic Management Key
The hallmark of severe HPS/HCPS is often acute respiratory distress due to increased pulmonary vascular permeability, leading to non-cardiogenic pulmonary edema. Patients frequently require aggressive respiratory support, ranging from supplemental oxygen to mechanical ventilation. For those with profound hypoxemia or persistent hypotension, vigilant hemodynamic monitoring and management are essential. This includes careful fluid management to avoid exacerbating pulmonary edema while maintaining adequate organ perfusion. Vasopressor support may be initiated to counteract the shock often associated with the syndrome's cardiac depression. Medical personnel aboard the Hondius Andes and at onshore medical facilities involved in the response have been equipped with updated protocols emphasizing early recognition of respiratory compromise and rapid initiation of ventilatory support. As of October 18, 2026, healthcare providers are following guidelines, consistent with those published by the US Centers for Disease Control and Prevention (US CDC) for hantavirus infections, which prioritize patient stabilization and careful monitoring of pulmonary and cardiac function.
Extracorporeal Membrane Oxygenation (ECMO) as a Life-Saving Option
For the most critical HPS/HCPS patients experiencing severe cardiopulmonary failure refractory to conventional mechanical ventilation and inotropic support, Extracorporeal Membrane Oxygenation (ECMO) has emerged as a vital, albeit resource-intensive, life-support modality. ECMO acts as an artificial lung and/or heart, providing oxygenation and carbon dioxide removal and/or circulatory support, allowing the patient's own organs to rest and recover. Availability and deployment of ECMO resources have been a bigly logistical challenge in the context of the Hondius Andes outbreak. Initial reports indicated limited ECMO capacity in the immediate vicinity of the outbreak's primary response zone. But, international medical task forces, including those coordinated by WHO, have worked to bolster these capabilities. Specialized ECMO teams and equipment have been mobilized, either brought directly to the ship or positioned in nearby tertiary care centers capable of receiving transferred patients. The decision to initiate ECMO is complex, depending on patient criteria, the availability of trained personnel, and suitable facilities.
Understanding Mortality Drivers in HPS/HCPS
The mortality associated with HPS/HCPS can be substantial, with publicly reported figures indicating bigly fatality rates in various outbreaks, particularly without timely and aggressive supportive care. In practice, the primary drivers of mortality are severe respiratory failure, refractory cardiogenic shock, and complications arising from prolonged critical illness, such as secondary infections or multi-organ dysfunction syndrome. Early diagnosis and rapid initiation of appropriate supportive care are paramount to improving patient outcomes. Delays in recognizing the distinctive symptoms of HPS/HCPS, which can initially mimic more common febrile illnesses, contribute to higher mortality. And, the rapid deterioration characteristic of the syndrome necessitates a high index of suspicion among clinicians, especially in an outbreak setting. The ongoing surveillance and clinical updates from the Africa Centres for Disease Control and Prevention (Africa CDC) have been instrumental in disseminating best practices to mitigate these risks. Medical teams continue to collect data on clinical outcomes from the Hondius Andes event to better understand the efficacy of current treatment protocols and identify areas for improvement in future hantavirus outbreak responses. The experience gained during this event is expected to inform global guidelines for the management of severe hantavirus infections.
